AMGEN INC (AMGN)

↓ Download CSV

CIK 0000318154 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, AMGEN INC reported revenue of $36.75B, up 10.0% from the prior year. The company was profitable, with a net margin of 21.0%.

Key ratios (FY2025)

24.7%
Operating margin
21.0%
Net margin
89.1%
Return on equity
+10.0%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$36.75B$33.42B$28.19B$26.32B$25.98B$25.42B$23.36B
Cost of Revenue$12.04B$12.86B$8.45B$6.41B$6.45B$6.16B$4.36B$4.10B$4.07B$4.16B
Operating Income$9.08B$7.26B$7.90B$9.57B$7.64B$9.14B$9.67B$10.26B$9.97B$9.79B
Net Income$7.71B$4.09B$6.72B$6.55B$5.89B$7.26B$7.84B$8.39B$1.98B$7.72B
EPS (Diluted)$14.23$7.56$12.49$12.11$10.28$12.31$12.88$12.62$2.69$10.24
Total Assets$90.59B$91.84B$97.15B$65.12B$61.16B$62.95B$59.71B$66.42B$79.95B$77.63B
Shareholders' Equity$8.66B$5.88B$6.23B$3.66B$6.70B$9.41B$9.67B$12.50B$25.24B$29.88B
Cash & Equivalents$9.13B$11.97B$10.94B$7.63B$7.99B$6.27B$6.04B$6.95B$3.80B$3.24B
Operating Cash Flow$9.96B$11.49B$8.47B$9.72B$9.26B$10.50B$9.15B$11.30B$11.18B$10.35B
Capital Expenditures$1.86B$1.10B$1.11B$936.00M$880.00M$608.00M$618.00M$738.00M$664.00M$738.00M
Shares Outstanding542.00M541.00M538.00M541.00M573.00M590.00M609.00M665.00M735.00M754.00M
Dividends Per Share$9.66$9.13$8.64$7.95$7.22$6.56$5.95$5.41$4.77$4.15